Cerevel Therapeutics Holdings, Inc.

NASDAQ:CERE

44.96 (USD) • At close July 31, 2024
Bedrijfsnaam Cerevel Therapeutics Holdings, Inc.
Symbool CERE
Munteenheid USD
Prijs 44.96
Beurswaarde 8,191,487,560
Dividendpercentage 0%
52-weken bereik 19.59 - 44.99
Industrie Biotechnology
Sector Healthcare
CEO Mr. Ronald C. Renaud Jr., M.B.A., MBA
Website https://www.cerevel.com

An error occurred while fetching data.

Over Cerevel Therapeutics Holdings, Inc.

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial

Vergelijkbare Aandelen

Amedisys, Inc. logo

Amedisys, Inc.

AMED

91.86 USD

Guardant Health, Inc. logo

Guardant Health, Inc.

GH

37.5 USD

iRhythm Technologies, Inc. logo

iRhythm Technologies, Inc.

IRTC

103.16 USD

Novavax, Inc. logo

Novavax, Inc.

NVAX

8.55 USD

Arrowhead Pharmaceuticals, Inc. logo

Arrowhead Pharmaceuticals, Inc.

ARWR

18.93 USD

Surgery Partners, Inc. logo

Surgery Partners, Inc.

SGRY

20.23 USD

LivaNova PLC logo

LivaNova PLC

LIVN

47.63 USD

CRISPR Therapeutics AG logo

CRISPR Therapeutics AG

CRSP

39.04 USD

QuidelOrtho Corporation logo

QuidelOrtho Corporation

QDEL

40.27 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)